<DOC>
	<DOCNO>NCT01548170</DOCNO>
	<brief_summary>Sunitinib ATP competitive tyrosine kinase inhibitor several membrane receptor include VEGFR-1 , -2 , -3 , PDGFR-α -β , c-KIT , CSF-1R , FLT-3 , RET . Through molecular mode action , sunitinib able avoid tumoral angiogenesis proliferation . Sunitinib already approve FDA , EMEA AEMPS treatment patient metastatic renal cell carcinoma metastatic gastrointestinal stromal tumor ( GIST ) progression intolerance imatinib . Suntinib recently report superior placebo term response rate ( 9.3 % vs. 0 % ; p &lt; 0.05 ) , progression free survival ( 11.4 vs. 5,5 month ; HR 0.41 ; p &lt; 0.05 ) , overall survival ( HR 0.40 ; p &lt; 0.05 ) administer phase 3 trial patient advance pancreatic neuroendocrine tumor ( NETs ) . Sunitinib expensive drug drain budget health public system therefore demand rational drug use . Sunitinib metabolize CYP3A4 , belong P450 cytochrome system liver . Most drug eliminate faeces 16 % urine . Sunitinib food-effect take meal . Pharmacokinetics parameter differ cancer patient healthy volunteer . Houk et al . Showed area curve plasmatic concentration sunitinib active metabolite correlate clinical outcome . In word , high plasma concentration area curve high rate radiological response , progression free overall survival rate . Ketoconazol antifungal drug inhibits CY3A4 induce elevation peak plasma level drug administer simultaneously metabolized system . In label sheet sunitinib say ketoconazol induce 49 % 51 % increase plasmatic sunitinib Cmax AUC0-∞ drug administer together . This fact make investigatorspropose administer drug simultaneously investigator could reduce sunitinib dose low metabolization similar plasma concentration . The dose reduction would impact drug cost . Here investigator propose determine optimal combination dose sunitinib ( 25 mg 37.5 mg ) ketoconazol ( 200mg 400mg ) investigator could plasmatic bioequivalent concentration compare single dose sunitinib 50mg . Each volunteer assign treatment arm ( Arm A Arm B ) . Volunteers include Arm A take : sunitinib 50 mg , sunitinib 37.5 mg + ketoconazole 200 mg sunitinib 37.5 mg + 400 mg ketoconazole . Volunteers include Arm B take : sunitinib 50 mg , sunitinib 25 mg + ketoconazole 200 mg sunitinib 25 mg + 400 mg ketoconazole</brief_summary>
	<brief_title>To Assess Interaction Between Sunitinib Ketoconazole Reduce Dose Cost Sunitinib</brief_title>
	<detailed_description>This phase I , pilot , open , randomize , parallel , cross-over trial ass interaction three different dose level sunitinib ( 50 mg , 37.5 mg , 25 mg ) two dose level ketoconazole ( 200 mg 400 mg ) 12 healthy volunteer ( 6 voluunteers group treatment ) Each volunteer assign treatment arm ( Arm A Arm B . Volunteers include Arm A take : sunitinib 50 mg , sunitinib 37.5 mg + ketoconazole 200 mg sunitinib 37.5 mg + 400 mg ketoconazole . Volunteers include Arm B take : sunitinib 50 mg , sunitinib 25 mg + ketoconazole 200 mg sunitinib 25 mg + 400 mg ketoconazole</detailed_description>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Healthy individual men give write consent participate study , receive information design , project objective , risk moment refuse cooperation . Age 18 35 year . Subjects BMI 19 28 . Healthy subject , without organic psychological pathology . Clinical history physical examination within normal limit . Lack clinically relevant abnormality blood test ( hematology , biochemistry , virology ) urine test Vital sign electrocardiographic record normal range . Subjects suffer organic psychological pathology . Prior inclusion volunteer consider security parameter mention protocol ( biochemical marker kidney damage / liver normal range set laboratory ) . Subjects received prescription drug treatment last 15 day medication within 48 hour receive study medication . Known hypersensitivity drug Suspected drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Ketoconazol</keyword>
	<keyword>interaction , Phase I</keyword>
</DOC>